Skip to content
ppharmaranks
Menu
Class IITerminated

Cefixime for Oral Suspension 100mg/5mL recall

FDA recall D-0274-2024 · initiated Jan 3, 2024

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Feb 7, 2024How we research

Lupin Pharmaceuticals Inc. recalled Cefixime for Oral Suspension 100mg/5mL in Jan 2024 — an FDA Class II recall (D-0274-2024) because Failed Impurities/Degradation Specifications.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Failed Impurities/Degradation Specifications

An impurity above the accepted limit

A by-product of manufacturing or storage exceeded the limit the FDA accepts. Nitrosamines are the common example: the concern is long-term exposure, not immediate danger from one dose.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot #: F304833, Exp 06/2025

Quantity recalled: 4,608 Bottles

Details

Product
Cefixime for Oral Suspension 100mg/5mL, 50 mL bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, Manufactured by:Lupin Limited, Mandideep 462 046 INDIA, NDC 68180-405-01
Recalling company
Lupin Limited
Classification
Class II
Status
Terminated
Type
Voluntary: Firm initiated
Distribution
Nationwide in the USA
Initiated
Jan 3, 2024
FDA report date
Feb 7, 2024
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Cefixime for Oral Suspension 100mg/5mL recalled?
Lupin Pharmaceuticals Inc. recalled Cefixime for Oral Suspension 100mg/5mL in Jan 2024 — an FDA Class II recall (D-0274-2024) because Failed Impurities/Degradation Specifications. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Cefixime for Oral Suspension 100mg/5mL recalled?
Per the FDA enforcement record, the reason for recall D-0274-2024 was: Failed Impurities/Degradation Specifications
Is a recalled Cefixime for Oral Suspension 100mg/5mL dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Cefixime for Oral Suspension 100mg/5mL are affected?
Distributed: Nationwide in the USA. The recall covers these lots — Lot #: F304833, Exp 06/2025. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0274-2024.

Source: openFDA Drug Enforcement record D-0274-2024

← All drug recalls